Register an account to search through 14,000+ stocks! 

Ad

CLINC – Clinigen Group PLC

Ad

✘ NOT COMPLIANT

—X—

Biotechnology & Medical Research | UK

Business: PASS

Clinigen Group PLC has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.

Financials: FAIL

The financials fail all the three standards we check against.

FTSE

Debt/A39.29%
Cash/A7.78%
(AR+C)/A19.35%

AAOIFI

Debt/MC34.89%
Cash/MC%

DJIM

Debt/24MC45.63%
Cash/24MC9.03%
AR/24MC13.44%

Total Analysts: 7

Recommendation Rating

2

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 10.9

Low: 9.2

High: 12.6

Market cap1659262483
Assets1473410580
Dividends per Share0.11
Revenue Growth-0.2

Clinigen Group plc is a United Kingdom-based pharmaceutical services and products company. The Company’s principal activities are focused on providing healthcare professionals (HCPs) and their patients with access to medicines. It operates through two segments: Services and Products. Its product brands include ACETYLCYSTEINE, COLECALCIFEROL, CARDIOXANE, ERWINASE / ERWINAZE, ETHYOL, FOLIC ACID COLONIS, FOSCAVIR, GABAPENTIN COLONIS, GLYCOPYRRONIUM BROMIDE, ILOPROST, IMUKIN / IMMUKIN / IMMUKINE, METFORMIN COLONIS, NORTRIPTYLINE COLONIS, PROLEUKIN and SAVENE, among others. The services provided by the Company includes clinical supplies management, managed access programs, real world data and medical science liaison (MSL). It operates in locations across North America, Europe, Africa, Japan and Asia Pacific. Its subsidiaries include Clinigen Healthcare B.V., Clinigen Clinical Trials Limited, Link Healthcare Singapore Pte. Limited and Clinigen South Africa (Pty) Limited, among others.

✘ FTSE✘ AAOIFI✘ DJIM

✘ NOT COMPLIANT

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.

Ad

Responses